1
|
Hori S, Nomura T and Sakaguchi S: Control
of regulatory T cell development by the transcription factor Foxp3.
Science. 299:1030–1031. 2003. View Article : Google Scholar
|
2
|
Schubert LA, Jeffery E, Zhang Y, Ramsdell
F and Ziegler SF: Scurfin (FOXP3) acts as a repressor of
transcription and regulates T cell activation. J Biol Chem.
276:37672–37679. 2001. View Article : Google Scholar : PubMed/NCBI
|
3
|
Zuo T, Wang L, Morrison C, Chang X, Zhang
H, Li W and Liu Y, Wang Y, Liu X, Chan MW, Liu JQ, Love R, Liu CG,
Godfrey V, Shen R, Huang TH, Yang T, Park BK, Wang CY, Zheng P and
Liu Y: FOXP3 is an X-linked breast cancer suppressor gene and an
important repressor of HER-2/ErbB2 oncogene. Cell. 129:1275–1286.
2007. View Article : Google Scholar : PubMed/NCBI
|
4
|
Zuo T, Liu R, Zhang H, Chang X and Liu Y,
Wang L, Zheng P and Liu Y: FOXP3 is a novel transcriptional
repressor for the breast cancer oncogene SKP2. J Clin Invest.
117:3765–3773. 2007.PubMed/NCBI
|
5
|
Kim J, Lahl K, Hori S, Loddenkemper C,
Chardhry A, deRoos P, Rudensky A and Sparwasser T: Depletion of
Foxp3+ cells leads to induction of autoimmunity by
specific ablation of regulatory T cells in genetically targeted
mice. J Immunol. 183:7631–7634. 2009.PubMed/NCBI
|
6
|
Hinz S, Pagerols-Raluy L, Oberg H,
Ammerpohl O, Grüssel S, Sipos B, Grützmann R, Pilarsky C,
Ungefroren H, Saeger H, Klöppel G, Kabelitz D and Kalthoff H: Foxp3
expression in pancreatic carcinoma cells as a novel mechanism of
immune evasion in cancer. Can Res. 67:8344–8350. 2007. View Article : Google Scholar : PubMed/NCBI
|
7
|
Wu Y, Borde M, Heissmeyer V, Feuerer M,
Lapan AD, Stroud JC, Bates DL, Guo L, Han A, Ziegler SF, Mathis D,
Benoist C, Chen L and Rao A: FOXP3 controls regulatory T cell
function through cooperation with NFAT. Cell. 126:375–387. 2006.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Heinze E, Baldwin S, Chan G, Hansen J,
Song J, Clements D, Aragon R, Nishimura R, Reeves M and Weisbart R:
Antibody-mediated protein therapy induces apoptosis in cancer cells
in vitro and inhibits metastasis in vivo. Int J
Oncol. 35:167–173. 2009.PubMed/NCBI
|
9
|
Ziegler SF: FOXP3: Of mice and men. Annu
Rev Immunol. 24:209–226. 2006. View Article : Google Scholar : PubMed/NCBI
|
10
|
Weisbart RH, Stempniak M, Harris S, Zack
DJ and Ferreri K: An autoantibody is modified for use as a delivery
system to target the cell nucleus: Therapeutic implications. J
Autoimmun. 11:539–546. 1998. View Article : Google Scholar : PubMed/NCBI
|
11
|
Hansen JE, Tse CM, Chan G, Heinze ER,
Nishimura RN and Weisbart RH: Intranuclear protein transduction
through a nucleoside salvage pathway. J Biol Chem. 282:20790–20793.
2007. View Article : Google Scholar : PubMed/NCBI
|
12
|
Hansen JE, Fischer LK, Chan G, Chang SS,
Baldwin SW, Aragon RJ, Carter JJ, Lilly M, Nishimura RN, Reeves ME
and Weisbart RH: Antibody-mediated p53 protein therapy prevents
liver metastasis in vivo. Cancer Res. 67:1769–1774. 2007.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Katoh H, Zheng P and Liu Y: Signalling
through FOXP3 as an X-Linked tumor suppressor. Int J Biochem Cell
Biol. 42:1784–1787. 2010. View Article : Google Scholar : PubMed/NCBI
|
14
|
Lopes JE, Torgerson TR, Schubert LA,
Anover SD, Ocheltree EL, Ochs HD and Ziegler SF: Analysis of FOXP2
reveals multiple domains required for its function as a
transcriptional repressor. J Immunol. 177:3133–3142. 2006.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Matas D, Sigal A, Stambolsky P, Milyavsky
M, Weisz L, Schwartz D, Goldfinger N and Rotter V: Integrity of the
N-terminal transcription domain of p53 is required for mutant p53
interference with drug-induced apoptosis. EMBO J. 20:4163–4172.
2001. View Article : Google Scholar : PubMed/NCBI
|
16
|
Haupt S, Berger M, Goldberg Z and Haupt Y:
Apoptosis – the p53 network. J Cell Sci. 116:4077–4085. 2003.
|
17
|
Zhou Z, Song X, Li B and Greene MI: FOXP3
and its partners: structural and biochemical insights into the
regulation of FOXP3 activity. Immunol Res. 42:19–28. 2008.
View Article : Google Scholar : PubMed/NCBI
|